



NEWSLETTER

SEPTEMBER 2025
ISSUE 3

MAHs INVOICING PROCESS FOR 2026

During the most recent OSMR General Assembly, which was held on August 26th, the financial outlook and market landscape for the upcoming year were reviewed.

After careful consideration, it was agreed to maintain *the operational fee for the NMVS at the same level as last year: 9,000 EUR/MAH*, and to *lower the affiliation tax to the amount of 3,000 EUR/MAH*.

This decision reflects OSMR's commitment to providing stability and predictability for our stakeholders, while ensuring the continued, secure operation of the National Medicines Verification System.

The invoicing process will start on September 15th.



NMVS RELEASE – CORE 7.0 & REPORTING TOOL 7.0

A new version of the National Medicines Verification System (NMVS) will be installed in the ***PROD environment and validated starting with 22.09.2025.***

We are proud to share that ***Romania***, through OSMR's Technical Team, will once again serve as a ***Pilot country for this upcoming system release, ensuring that the latest version is thoroughly tested and ready to deliver even greater reliability and security.***

The entire team believes that maintaining a secure and reliable system requires constant evolution, thus every effort is made to ensure the highest standards in safeguarding patients.



NMVS RELEASE – CORE 7.0 & REPORTING TOOL 7.0

The new features do not impact the End-Users' interface, these include:

❖ *Development of the history functionality –*

New interfaces will be implemented to visualize the history of changes associated with clients, users, and roles.

These views will be integrated into the new system and will offer a clearer and more intuitive presentation of historical data, contributing to better traceability and efficiency in daily use and in audit contexts.

❖ *Technical improvements (enhanced User Interface technology);*

❖ *System security enhancements;*

❖ *Fixes for defects reported during testing of previous NMVS versions.*

